RU2008118995A - Антагонист аденозинового рецептора а2а для изготовления лекарственного средства для лечения фибрилляции предсердий - Google Patents
Антагонист аденозинового рецептора а2а для изготовления лекарственного средства для лечения фибрилляции предсердий Download PDFInfo
- Publication number
- RU2008118995A RU2008118995A RU2008118995/15A RU2008118995A RU2008118995A RU 2008118995 A RU2008118995 A RU 2008118995A RU 2008118995/15 A RU2008118995/15 A RU 2008118995/15A RU 2008118995 A RU2008118995 A RU 2008118995A RU 2008118995 A RU2008118995 A RU 2008118995A
- Authority
- RU
- Russia
- Prior art keywords
- use according
- antagonists
- antagonist
- derivatives
- structural formula
- Prior art date
Links
- 206010003658 Atrial Fibrillation Diseases 0.000 title claims abstract 3
- 229940121359 adenosine receptor antagonist Drugs 0.000 title claims abstract 3
- 238000004519 manufacturing process Methods 0.000 title claims abstract 3
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 title claims abstract 3
- 101150051188 Adora2a gene Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 claims abstract 20
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims abstract 4
- LIZOFKWBNVAHPD-UHFFFAOYSA-N 2h-triazolo[4,5-d]triazine Chemical class C1=NN=NC2=C1NN=N2 LIZOFKWBNVAHPD-UHFFFAOYSA-N 0.000 claims abstract 2
- XSJMOLCRLLDSFM-UHFFFAOYSA-N 2h-triazolo[4,5-f]quinoxaline Chemical class C1=CC2=NC=CN=C2C2=NNN=C21 XSJMOLCRLLDSFM-UHFFFAOYSA-N 0.000 claims abstract 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims abstract 2
- 241000124008 Mammalia Species 0.000 claims abstract 2
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- IQVRBWUUXZMOPW-PKNBQFBNSA-N istradefylline Chemical compound CN1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1\C=C\C1=CC=C(OC)C(OC)=C1 IQVRBWUUXZMOPW-PKNBQFBNSA-N 0.000 claims abstract 2
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 claims abstract 2
- 150000003014 phosphoric acid esters Chemical class 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- -1 1-prop-2-ynylpurin-2,6-dione Chemical compound 0.000 claims 1
- BCGFASHRDSXLNN-UHFFFAOYSA-N 2-propan-2-yl-4-(1,3-thiazol-2-yl)thieno[3,2-d]pyrimidine Chemical compound C=12SC=CC2=NC(C(C)C)=NC=1C1=NC=CS1 BCGFASHRDSXLNN-UHFFFAOYSA-N 0.000 claims 1
- SNGAHBASRUHSIU-UHFFFAOYSA-N C#CCC1=NC2=NC(=O)NC(=O)C2=N1 Chemical compound C#CCC1=NC2=NC(=O)NC(=O)C2=N1 SNGAHBASRUHSIU-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
1. Применение антагонистов аденозинового рецептора А2A для изготовления лекарственного средства для предупреждения и/или лечения фибрилляции предсердий у млекопитающего, включая человека. ! 2. Применение по п.1, в котором в качестве антагонистов А2A используют ксантиновые производные или их фармацевтически приемлемые соли. ! 3. Применение по п.2, в котором в качестве антагонистов А2A используют соединения, имеющие структурные формулы, выбранные из группы, включающей в себя ! ! 4. Применение по п.3, в котором в качестве антагониста А2A используют 8-[(Е)-2-(3,4-диметоксифенил)этенил]-1,3-диэтил-7-метилпурин-2,6-дион, имеющий вышеприведенную структурную формулу (3) ! ! 5. Применение по п.3, в котором в качестве антагониста А2A используют 3-(3-гидроксипропил)-8-[(Е)-2-(3-метоксифенил)этенил]-7-метил-1-проп-2-инилпурин-2,6-дион, имеющий вышеприведенную структурную формулу (6). ! 6. Применение по п.2, в котором в качестве антагониста А2A используют сложный эфир фосфорной кислоты и 3-(3-гидроксипропил)-8-[(Е)-2-(3-метоксифенил)этенил]-7-метил-1-проп-2-инилпурин-2,6-диона, имеющего вышеприведенную структурную формулу (6). ! 7. Применение по п.1, в котором в качестве антагонистов А2A используют пиразолопиримидиновые производные. ! 8. Применение по п.1, в котором в качестве антагонистов А2A используют триазолохиноксалиновые производные. ! 9. Применение по п.1, в котором в качестве антагонистов А2A используют триазолотриазиновые производные. ! 10. Применение по п.1, в котором в качестве антагонистов А2A используют соединения, имеющие структурные формулы, выбранные из группы, включающей в себя ! ! 11. Применение по п.10, в котором в качестве антагониста А2A используют 2-пропан-2-ил-4-(1,3-тиазо
Claims (11)
1. Применение антагонистов аденозинового рецептора А2A для изготовления лекарственного средства для предупреждения и/или лечения фибрилляции предсердий у млекопитающего, включая человека.
2. Применение по п.1, в котором в качестве антагонистов А2A используют ксантиновые производные или их фармацевтически приемлемые соли.
3. Применение по п.2, в котором в качестве антагонистов А2A используют соединения, имеющие структурные формулы, выбранные из группы, включающей в себя
4. Применение по п.3, в котором в качестве антагониста А2A используют 8-[(Е)-2-(3,4-диметоксифенил)этенил]-1,3-диэтил-7-метилпурин-2,6-дион, имеющий вышеприведенную структурную формулу (3)
5. Применение по п.3, в котором в качестве антагониста А2A используют 3-(3-гидроксипропил)-8-[(Е)-2-(3-метоксифенил)этенил]-7-метил-1-проп-2-инилпурин-2,6-дион, имеющий вышеприведенную структурную формулу (6).
6. Применение по п.2, в котором в качестве антагониста А2A используют сложный эфир фосфорной кислоты и 3-(3-гидроксипропил)-8-[(Е)-2-(3-метоксифенил)этенил]-7-метил-1-проп-2-инилпурин-2,6-диона, имеющего вышеприведенную структурную формулу (6).
7. Применение по п.1, в котором в качестве антагонистов А2A используют пиразолопиримидиновые производные.
8. Применение по п.1, в котором в качестве антагонистов А2A используют триазолохиноксалиновые производные.
9. Применение по п.1, в котором в качестве антагонистов А2A используют триазолотриазиновые производные.
10. Применение по п.1, в котором в качестве антагонистов А2A используют соединения, имеющие структурные формулы, выбранные из группы, включающей в себя
11. Применение по п.10, в котором в качестве антагониста А2A используют 2-пропан-2-ил-4-(1,3-тиазол-2-ил)тиено[2,3-е]пиримидин, имеющий структурную формулу (15).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200502545A ES2273599B1 (es) | 2005-10-14 | 2005-10-14 | Compuestos para el tratamiento de la fibrilacion auricular. |
| ESP200502545 | 2005-10-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008118995A true RU2008118995A (ru) | 2009-11-20 |
| RU2445099C2 RU2445099C2 (ru) | 2012-03-20 |
Family
ID=37962872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008118995/15A RU2445099C2 (ru) | 2005-10-14 | 2006-10-10 | Селективные антагонисты аденозинового рецептора a2a для изготовления лекарственного средства для лечения фибрилляции предсердий |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8012973B2 (ru) |
| EP (1) | EP1949903B8 (ru) |
| JP (1) | JP2009511551A (ru) |
| CN (1) | CN101325956B (ru) |
| AT (1) | ATE553763T1 (ru) |
| AU (1) | AU2006303240B2 (ru) |
| BR (1) | BRPI0617369A2 (ru) |
| CA (1) | CA2626020A1 (ru) |
| DK (1) | DK1949903T3 (ru) |
| ES (2) | ES2273599B1 (ru) |
| MX (1) | MX2008004886A (ru) |
| RU (1) | RU2445099C2 (ru) |
| WO (1) | WO2007045705A2 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2595028T3 (es) * | 2011-10-17 | 2016-12-27 | F. Hoffmann-La Roche Ag | Diagnóstico basado en Troponina y BNP de pacientes en riesgo y causa de ictus |
| CZ305625B6 (cs) * | 2014-05-06 | 2016-01-13 | Vysoká škola chemicko- technologická v Praze | Kofein-8-hydrazony jako nová cytostatika pro léčbu onkologických onemocnění |
| WO2017008205A1 (en) * | 2015-07-10 | 2017-01-19 | Merck Sharp & Dohme Corp. | Substituted aminoquinazoline compounds as a2a antagonist |
| JP7071389B2 (ja) * | 2017-03-07 | 2022-05-18 | グアンジョウ マキシノベル ファーマシューティカルズ カンパニー リミテッド | アミノピリミジン縮合５員複素環化合物、その中間体、製造方法、薬物組成物および使用 |
| EP3802540A1 (en) | 2018-06-04 | 2021-04-14 | Exscientia Ltd | Pyrazolopyrimidine compounds as adenosine receptor antagonists |
| CN108864114B (zh) * | 2018-06-04 | 2020-11-06 | 应世生物科技(南京)有限公司 | 选择性a2a受体拮抗剂 |
| EP4146341A4 (en) * | 2020-05-06 | 2024-06-26 | Ohio State Innovation Foundation | Compositions and methods for treating atrial fibrillation |
| KR102675647B1 (ko) * | 2021-06-30 | 2024-06-18 | 단국대학교 천안캠퍼스 산학협력단 | 인간치아줄기세포의 상아모세포로의 분화를 위한 신규 화합물 및 이의 의학적 용도 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US599387A (en) * | 1898-02-22 | Cabinet | ||
| US4772607A (en) * | 1986-05-20 | 1988-09-20 | Warner-Lambert Company | Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor |
| US4780464A (en) * | 1986-12-08 | 1988-10-25 | Warner-Lambert Company | (1,2,4)triazolo(4,3-a)quinoxaline-4-amines |
| CA2094270C (en) | 1990-10-18 | 1997-01-21 | Fumio Suzuki | Xanthine derivatives |
| GB9124968D0 (en) * | 1991-11-25 | 1992-01-22 | Ici Plc | Chemical process |
| US5484920A (en) | 1992-04-08 | 1996-01-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for Parkinson's disease |
| US5543415A (en) | 1992-07-08 | 1996-08-06 | Kyowa Hakko Kogyo Co., Ltd. | Antidepressants |
| IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
| AU7237294A (en) | 1993-07-27 | 1995-02-28 | Kyowa Hakko Kogyo Co. Ltd. | Remedy for parkinson's disease |
| US5736528A (en) * | 1993-10-28 | 1998-04-07 | University Of Florida Research Foundation, Inc. | N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists |
| US5703085A (en) | 1994-02-23 | 1997-12-30 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
| IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| US6051578A (en) * | 1996-02-12 | 2000-04-18 | Pfizer Inc. | Pyrazolopyrimidines for treatment of CNS disorders |
| US6060478A (en) * | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
| ATE257156T1 (de) | 1997-03-24 | 2004-01-15 | Kyowa Hakko Kogyo Kk | (1,2,4)triazolo(1,5-c)pyrimidin-derivate |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| EP1016407B1 (en) | 1997-09-05 | 2006-05-10 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives for treating brain ischemia |
| EP0975345A1 (en) | 1997-11-26 | 2000-02-02 | Cerebrus Pharmaceuticals Limited | (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders |
| USRE39112E1 (en) | 1998-01-05 | 2006-05-30 | Eisai Co., Ltd. | Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes |
| AU2639299A (en) | 1998-02-24 | 1999-09-15 | Kyowa Hakko Kogyo Co. Ltd. | Remedies/preventives for parkinson's disease |
| DE19930558A1 (de) | 1998-07-24 | 2000-01-27 | Marquardt Gmbh | Elektrischer Schalter |
| GB9819382D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
| GB9819384D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
| WO2000014084A1 (en) * | 1998-09-04 | 2000-03-16 | The Procter & Gamble Company | Substituted dihydrobenzopyrans useful as antiarrhythmic agents |
| WO2000069464A1 (en) | 1999-05-12 | 2000-11-23 | Fujisawa Pharmaceutical Co., Ltd. | Novel use |
| US6545002B1 (en) | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
| GB9915437D0 (en) | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
| NZ516260A (en) | 1999-07-02 | 2004-08-27 | Eisai Co Ltd | Fused imidazole compounds and remedies for diabetes mellitus |
| JP3347691B2 (ja) * | 1999-07-05 | 2002-11-20 | プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド | 抗不整脈及び抗細動剤として有用な新規４−オキソ環式尿素類 |
| ES2190422T3 (es) | 1999-08-31 | 2003-08-01 | Univ Vanderbilt | Antagonistas selectivos de receptores de adenosina a2b. |
| US6355653B1 (en) | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
| DE19947154A1 (de) | 1999-10-01 | 2001-10-04 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
| US6194366B1 (en) | 1999-11-16 | 2001-02-27 | Esc, Inc. | Post chemical-mechanical planarization (CMP) cleaning composition |
| AUPQ441499A0 (en) | 1999-12-02 | 2000-01-06 | Fujisawa Pharmaceutical Co., Ltd. | Novel compound |
| US6258793B1 (en) * | 1999-12-03 | 2001-07-10 | Cv Therapeutics, Inc. | N6 heterocyclic 5′ modified adenosine derivatives |
| MY125533A (en) * | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| YU63802A (sh) | 2000-02-25 | 2005-06-10 | F. Hoffmann-La Roche Ag. | Modulatori adenozinskih receptora |
| CA2407013A1 (en) | 2000-04-26 | 2002-10-22 | Eisai Co., Ltd. | Pharmaceutical composition promoting defecation |
| AU6808901A (en) | 2000-05-26 | 2001-12-11 | Schering Corp | Adenosine a2a receptor antagonists |
| CA2413086C (en) | 2000-06-21 | 2011-06-28 | Alexander Alanine | Benzothiazole derivatives |
| EP1308441B1 (en) | 2000-08-11 | 2009-10-07 | Eisai R&D Management Co., Ltd. | 2-aminopyridine compounds and use thereof as drugs |
| GB0100620D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical cokpounds V |
| IL160878A0 (en) | 2001-10-15 | 2004-08-31 | Schering Corp | Imidazo (4,3-e)-1,2,4-triazolo (1,5-c) pyrimidines as adenosine a2a receptor antagonists |
| US6599901B1 (en) * | 2001-11-19 | 2003-07-29 | Hoffman-La Roche Inc. | Pyridone substituted benzothiazole derivatives |
| MXPA04005209A (es) | 2001-11-30 | 2004-08-19 | Schering Corp | Antagonistas del receptor de adenosina a2a. |
| MXPA04005158A (es) | 2001-11-30 | 2004-08-11 | Schering Corp | Antagonistas receptores de adenosina a2a biciclica de (1.2.4]- triazol. |
| PE20030739A1 (es) | 2001-11-30 | 2003-08-28 | Schering Corp | Antagonistas del receptor de adenosina a2a |
| AU2002357295A1 (en) | 2001-12-18 | 2003-06-30 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
| US20050043315A1 (en) | 2002-01-02 | 2005-02-24 | Hideo Tsutsumi | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them |
| ES2208063B1 (es) | 2002-04-01 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida. |
| AU2002950853A0 (en) | 2002-08-19 | 2002-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compound and pharmaceutical use thereof |
| WO2004019949A1 (en) | 2002-08-30 | 2004-03-11 | Kyowa Hakko Kogyo Co. Ltd. | Adenosine a2a receptor antagonists for treating restless legs syndrome or related disorders |
| US20060058320A1 (en) | 2002-09-24 | 2006-03-16 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4] Triazolo[1,5-c]pyrimidine derivatives |
| EP2269596A3 (en) | 2002-12-19 | 2011-09-14 | Schering Corporation | Use of adenosine A2a receptor antagonists for the treatment of extrapyramidal syndrome and other movement disorders |
| EP1613629A1 (en) * | 2003-03-27 | 2006-01-11 | Pfizer Products Inc. | Substituted 4-amino 1,2,4 triazolo 4,3-a quinoxalines |
| WO2004092177A1 (en) | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
| PE20050141A1 (es) | 2003-04-23 | 2005-04-01 | Schering Corp | DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA |
| ES2326075T3 (es) | 2003-10-03 | 2009-09-30 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Arilidenopiridinas y arilidenopirimidinas y su uso como antagonistas del receptor de adenosina a2a. |
| TW200524887A (en) | 2003-10-27 | 2005-08-01 | Lundbeck & Co As H | N-thiazol-2-yl-benzamide derivatives |
| JP4650419B2 (ja) | 2003-10-27 | 2011-03-16 | アステラス製薬株式会社 | ピラジン誘導体およびその医薬的使用 |
| CA2547248A1 (en) | 2003-12-01 | 2005-06-16 | Schering Corporation | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines |
| BRPI0417478A (pt) | 2003-12-15 | 2007-05-08 | Almirall Prodesfarma Ag | 2,6-bis-heteroaril-4-aminopirimidinas como antagonistas de receptor de adenosina |
-
2005
- 2005-10-14 ES ES200502545A patent/ES2273599B1/es not_active Expired - Fee Related
-
2006
- 2006-10-10 ES ES06830873T patent/ES2386377T3/es active Active
- 2006-10-10 AU AU2006303240A patent/AU2006303240B2/en not_active Ceased
- 2006-10-10 BR BRPI0617369-1A patent/BRPI0617369A2/pt not_active IP Right Cessation
- 2006-10-10 RU RU2008118995/15A patent/RU2445099C2/ru not_active IP Right Cessation
- 2006-10-10 US US12/090,115 patent/US8012973B2/en not_active Expired - Fee Related
- 2006-10-10 AT AT06830873T patent/ATE553763T1/de active
- 2006-10-10 WO PCT/ES2006/000564 patent/WO2007045705A2/es not_active Ceased
- 2006-10-10 CN CN200680046601XA patent/CN101325956B/zh not_active Expired - Fee Related
- 2006-10-10 JP JP2008535047A patent/JP2009511551A/ja active Pending
- 2006-10-10 CA CA002626020A patent/CA2626020A1/en not_active Abandoned
- 2006-10-10 MX MX2008004886A patent/MX2008004886A/es active IP Right Grant
- 2006-10-10 EP EP06830873A patent/EP1949903B8/en not_active Not-in-force
- 2006-10-10 DK DK06830873.3T patent/DK1949903T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2008004886A (es) | 2009-03-02 |
| WO2007045705A3 (es) | 2007-06-14 |
| ES2273599B1 (es) | 2008-06-01 |
| EP1949903A2 (en) | 2008-07-30 |
| ATE553763T1 (de) | 2012-05-15 |
| AU2006303240B2 (en) | 2012-07-12 |
| EP1949903B8 (en) | 2012-05-23 |
| EP1949903B1 (en) | 2012-04-18 |
| ES2273599A1 (es) | 2007-05-01 |
| RU2445099C2 (ru) | 2012-03-20 |
| US8012973B2 (en) | 2011-09-06 |
| CN101325956A (zh) | 2008-12-17 |
| JP2009511551A (ja) | 2009-03-19 |
| DK1949903T3 (da) | 2012-07-30 |
| CN101325956B (zh) | 2012-02-29 |
| WO2007045705A2 (es) | 2007-04-26 |
| ES2386377T3 (es) | 2012-08-20 |
| US20090312332A1 (en) | 2009-12-17 |
| BRPI0617369A2 (pt) | 2011-07-26 |
| CA2626020A1 (en) | 2007-04-26 |
| AU2006303240A1 (en) | 2007-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2457842C2 (ru) | Способ предотвращения и лечения болезни печени с использованием антагонистов рецептора аденозина a2b | |
| Baraldi et al. | Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility | |
| EP2081431B1 (en) | Organic compounds | |
| US9006258B2 (en) | Method of treating female sexual dysfunction with a PDE1 inhibitor | |
| ES2645371T3 (es) | Compuestos orgánicos | |
| JP2015511245A5 (ru) | ||
| US20090053168A1 (en) | Treatments of b-cell proliferative disorders | |
| US20090047243A1 (en) | Combinations for the treatment of b-cell proliferative disorders | |
| EP2400970A1 (en) | Pde 1 inhibitors for ophthalmic disorders | |
| WO2010132127A1 (en) | Organic compounds | |
| JP2001097889A (ja) | Ｃｒｆアンタゴニストおよび関連組成物の使用 | |
| KR101292508B1 (ko) | 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도 | |
| WO2014127331A1 (en) | Novel uses | |
| WO2016022893A1 (en) | Organic compounds | |
| AR037680A1 (es) | Antagonistas del receptor de adenosina a2a de 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]-pirimidinas sustituidas, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos, solos o en combinacion para la elaboracion de un medicamento utiles para el tratamiento de enfermedades d | |
| RU2005136166A (ru) | 2-алкинил -и 2-алкенил-пиразол-[4, 3-е]-1. 2. 4-триазоло-[1. 5-с]-пиримидиновые антагонисты а рецептора аденозина | |
| RU2008118995A (ru) | Антагонист аденозинового рецептора а2а для изготовления лекарственного средства для лечения фибрилляции предсердий | |
| RU2019108259A (ru) | Комбинированная терапия для лечения гепатоцеллюлярной карциномы | |
| EP3964206A1 (en) | Compounds for the treatment of covid-19 | |
| JP2009511551A5 (ru) | ||
| ES2260061T3 (es) | Composiciones farmaceuticas para trastornos relacionados con la alimentacion. | |
| AU2012261721A1 (en) | Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists | |
| RU2003134646A (ru) | Конденсированные пиримидины в качестве антагонистов кортикотропинвысокобождающего фактора (crf) | |
| Preti et al. | Kenneth A. Jacobson, Athena M. Klutz, Dilip K. Tosh, Andrei A. Ivanov |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20131011 |